The way ahead for HEOR in biopharma should be built on increasing C-suite visibility and understanding of the value contribution that HEOR makes and demonstrating that a failure to invest in HEOR puts companies at a competitive disadvantage, especially in the face of rising regulatory and payer expectations for evidence.
The post Health Economics and Outcomes Research: Biopharma’s Underappreciated Value Creator appeared first on MedCity News.
